TY - JOUR T1 - Predictors of Arterial Stiffness in Adolescents and Adults with Type 1 Diabetes: A Cross-Sectional Study JF - medRxiv DO - 10.1101/2021.07.14.21260516 SP - 2021.07.14.21260516 AU - Kaitlin M. Love AU - William B. Horton AU - James T. Patrie AU - Linda A. Jahn AU - Lee M. Hartline AU - Eugene J. Barrett Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/07/16/2021.07.14.21260516.abstract N2 - Introduction Individuals with type 1 diabetes have increased arterial stiffness compared to age-matched healthy controls. Our aim was to determine which hemodynamic and demographic factors predict arterial stiffness in this population.Research Design and Methods Carotid-femoral pulse wave velocity (cfPWV) was examined in 41 young adults and adolescents with type 1 diabetes without microvascular complications. Two ordinary least squares regression analyses were performed to determine multivariate relationships between cfPWV [loge] and: 1) age, duration of diabetes, sex, and HbA1c, and 2) augmentation index (AIx), mean arterial pressure, flow-mediated dilation (FMD), and heart rate. We also examined differences in macrovascular outcome measures between sexes.Results Age, sex, and FMD provided unique predictive information about cfPWV in these participants with type 1 diabetes. Despite having similar cardiovascular risk factors, males had higher cfPWV compared to females but no differences were observed in other macrovascular outcomes (including FMD and AIx).Conclusions Only age, sex, and FMD were uniquely associated with arterial stiffness in adolescents and adults with uncomplicated type 1 diabetes. Females had less arterial stiffness and similar nitric-oxide dependent endothelial function compared to males. Larger, prospective investigation is warranted to determine the temporal order of and sex-differences in arterial dysfunction in type 1 diabetes.What is already known about this subject?A measure of central artery stiffness, carotid-femoral pulse wave velocity (cfPWV) predicts renal outcomes, cardiovascular events, and mortality in persons with type 1 diabetes.Age, race, mean arterial pressure, waist-to-height ratio/body mass index, presence of microalbuminuria have all been uniquely associated with cfPWV in populations with type 1 diabetes.The relationship between cfPWV and flow mediated dilation (FMD), a measure of nitric oxide dependent endothelial function at the brachial artery, has not been defined in type 1 diabetes, and the relationship between diabetes duration and these vascular measures are unclear.What are the new findings?Arterial stiffness and NO-dependent endothelial dysfunction were highly prevalent even within 5 years of diabetes diagnosis (16.7% and 83.3% respectively) in this cohort of adolescents and adults with uncomplicated type 1 diabetes.FMD was uniquely associated with cfPWV.Augmentation index (AIx), mean arterial pressure, and diabetes duration were not predictive of cfPWV.Despite a greater excess cardiovascular risk associated with type 1 diabetes in females compared to males, macrovascular function was no worse in females when examining sex differences. Females had a lower cfPWV and similar AIx and FMD compared to males.How might these results change the focus of research or clinical practice?Larger, prospective clinical investigation is needed in type 1 diabetes to determine the temporal order of and sex-differences in arterial dysfunction.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by research grants from the NIH (DK101944 and DK073059) to EJB and in part by the National Center For Advancing Translational Sciences of the National Institutes of Health under Award Numbers KL2TR003016/ULTR003015 (to KML and WBH as iTHRIV scholars). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All study protocols included in this cross-sectional study were approved by the University of Virginia Institutional Review Board for Health Sciences Research.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData contained in this manuscript is available upon request. ER -